Which drug classes are associated with an increased risk of suicidal thoughts or behaviors?

Drugs Associated with Suicidal Risk

All antidepressants carry an FDA black-box warning for increased suicidal ideation and behavior in patients up to age 24 years, with the absolute risk being small (1% vs 0.2% placebo, yielding a number needed to harm of 143), but this risk must be balanced against the substantially greater benefit of treating depression (number needed to treat of 3). 1

Primary Drug Classes with Suicidal Risk

Antidepressants (Highest Quality Evidence)

SSRIs and all antidepressant classes carry FDA-mandated black-box warnings for suicidality through age 24. The evidence shows:

• Absolute risk: 4% with medication vs 2% with placebo in pediatric trials (though reanalysis showed only 0.7% increased risk) 2
• Critical monitoring period: First few months of treatment and after dose changes 2
• Warning signs to monitor: New/increased suicidal thoughts, self-destructive behavior, anxiety/panic, agitation, aggressiveness, impulsivity, insomnia, irritability, akathisia (restlessness/pacing), extreme elation, or fast driven speech 2

Important nuance: The risk of not treating depression appears significantly higher than the risk of treatment. After FDA black-box warnings led to 22% reduction in antidepressant prescribing, youth suicide rates increased 14% in the US and 49% in the Netherlands 2. Only 1.6% of young suicide victims had recent SSRI exposure, suggesting most lacked antidepressant benefit at time of death 2.

Anticonvulsants (Strong Research Evidence)

Specific anticonvulsants show varying suicidal risk, with FDA warnings extending to this entire class 3:

• Highest risk medications (compared to topiramate reference):

  • Tiagabine (HR 2.41)
  • Oxcarbazepine (HR 2.07)
  • Lamotrigine (HR 1.84)
  • Valproate (HR 1.65)
  • Gabapentin (HR 1.42) 3

• Risk particularly elevated in younger patients, those with mood disorders, and epilepsy patients 3

Sedative-Hypnotics (Recent High-Quality Evidence)

Z-drugs and benzodiazepines show significant associations with suicidal behavior 4, 5:

• Z-drugs (zolpidem, eszopiclone, zaleplon): Associated with suicidal ideation (OR 2.44), planning (OR 1.44), and attempts (OR 1.45) even after adjusting for mental health factors 4, 5
• Sedative benzodiazepines (temazepam, triazolam, flurazepam): Associated with suicide attempts (OR 1.76) 4
• Alprazolam and zolpidem rank among top 5 medications with highest suicidal ideation reporting 5

Clinical caveat: Benzodiazepines may cause disinhibition leading to aggression and suicide attempts. They can also cause delirium and paradoxical agitation 6, 7. Phenobarbital shares these risks with high lethal potential in overdose 7.

Antipsychotics (Moderate Evidence)

Second and third-generation antipsychotics appear in frequent adverse event reports 5:

• Quetiapine, aripiprazole: High reporting frequency for suicidal ideation 5
• Important context: These medications are often used to treat suicidal patients, confounding the association 5
• Antipsychotics themselves can cause agitation and delirium 6

Other Medications with Reported Associations

• Trazodone: Associated with suicidal ideation (OR 2.33) 4
• Stimulants (amphetamine): High reporting frequency for suicidal ideation 5
• Duloxetine: Large number of suicidal ideation reports 5

Critical Clinical Algorithm

When prescribing any medication with suicidal risk:

1. Baseline assessment: Document current suicidal ideation, prior attempts, psychiatric comorbidities, substance use, and risk factors 2

2. Patient/family education: Provide specific warning signs (listed above) and instructions to contact physician immediately if these emerge 2

3. Monitoring schedule:

   • Weekly visits during first month
   • After any dose changes
   • Continue frequent monitoring through first 3 months 2, 1

4. Medication access control: Ensure third party monitors medication administration, especially for high-lethality drugs (tricyclics have high lethal potential; SSRIs have lower but not zero overdose risk) 1, 7

5. Means restriction: Confirm firearms removed from home and all medications locked up 2

Common Pitfalls to Avoid

• Don't withhold necessary treatment due to black-box warnings—untreated depression carries greater mortality risk than medication-associated suicidality 2
• Don't rely on "no-suicide contracts"—these are unproven for prevention, though refusal to agree signals high risk 2
• Don't miss akathisia with SSRIs—this motor restlessness is specifically linked to increased suicidality 7
• Don't prescribe tricyclic antidepressants to suicidal patients due to high lethality in overdose 7
• Don't use slow titration as excuse to delay monitoring—behavioral activation can occur even at low doses 1

Key Evidence Consideration

The association between drugs and suicidal ideation predicts actual suicide attempts: Analysis of 832 drugs in FDA adverse event data showed drugs associated with increased suicidal ideations had 131-fold stronger association with suicide attempts than non-suicidal adverse events 8. This validates that drug-induced suicidal thoughts are harbingers of serious outcomes, not benign epiphenomena.